Compare KPTI & FOFO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KPTI | FOFO |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.6M | 85.2M |
| IPO Year | 2013 | 2025 |
| Metric | KPTI | FOFO |
|---|---|---|
| Price | $6.75 | $11.41 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $22.17 | N/A |
| AVG Volume (30 Days) | ★ 174.4K | 54.2K |
| Earning Date | 11-03-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.36 |
| Revenue | ★ $142,530,000.00 | $3,117,608.00 |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $3.18 | N/A |
| P/E Ratio | ★ N/A | $33.25 |
| Revenue Growth | N/A | ★ 1597.65 |
| 52 Week Low | $3.51 | $4.63 |
| 52 Week High | $12.45 | $68.00 |
| Indicator | KPTI | FOFO |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | N/A |
| Support Level | $5.70 | N/A |
| Resistance Level | $7.48 | N/A |
| Average True Range (ATR) | 0.45 | 0.00 |
| MACD | 0.16 | 0.00 |
| Stochastic Oscillator | 69.78 | 0.00 |
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Hang Feng Technology Innovation Co Ltd is committed to providing comprehensive corporate management consulting and asset management services, tailored to address the specific needs of each client. Its goal is to empower its clients to design, implement, and achieve their unique business and investment objectives. Its business consists of two main segments: (i) corporate management consulting services and (ii) asset management services. The corporate management consulting services include Management consulting, and Regulatory compliance and governance consulting.